Phase I Trial of 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in Patients With Advanced Solid Tumors View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2018-2021

ABSTRACT

Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the instruction book for each cell. In some people with cancer, the genes that might have slowed the growth of their tumor were turned off. Researchers want to see if a new drug can turn the genes back on and slow the tumor growth. The drug is called Aza-TdC. Objective: To test the safety of Aza-TdC, and to find out the dose of this drug that can be safely given to humans. Eligibility: People ages 18 and older who have advanced cancer that has gotten worse after standard treatment, or for which no effective therapy exists Design: Participants will be screened with: Medical history Blood and urine tests Scans to measure their tumors Test to measure the electrical activity of the heart Participants will take the study drug by mouth. The drug is given in cycles. Each cycle is 21 days (3 weeks) long. Week 1 and week 2: participants will take the study drug once a day for 5 days. Then they will have 2 days without the drug. Week 3: no study drug is taken. This completes one cycle of treatment. For cycle 1, participants will repeat the screening tests several times. For all other cycles, participants will have blood tests and pregnancy tests. They will have scans of their tumor every 6 weeks. The cycle will be repeated as long as the participant tolerates the drug and the cancer is either stable or gets better. Sponsoring Institute: National Cancer Institute Detailed Description Background - Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two DNA hypomethylating nucleosides, 5-azacytidine (azacytidine) and 5-aza-2'-deoxycytidine (decitabine) have been approved by the FDA for the treatment of patients with myelodysplastic syndromes and certain leukemias. - The nucleoside analog 5-aza-4 -thio-2 -deoxycytidine (Aza-TdC) is incorporated into DNA, where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. DNMT1 can become trapped in a covalent complex with DNA, thus depleting free enzyme and inhibiting the normal maintenance methylation of CpG sites, resulting in re-activation of tumor suppressor genes. - Data suggest a correlation between Aza-TdC activity in solid tumor xenograft models and decreased levels of DNMT1. - Aza-TdC offers an improvement over traditional DNA methyltransferase inhibitors by virtue of a higher incorporation rate into DNA at lower levels of cytotoxicity; Aza-TdC has greater antitumor activity than another recently developed DNMT1 inhibitor, TdCyd, in some solid tumor xenograft models. Treatment with Aza-TdC is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules. Primary Objective: -To establish the safety, tolerability, and MTD of oral Aza-TdC administered daily for 5 days a week for 2 weeks, with one week off, q 21-day cycles, to patients with refractory solid tumors Secondary Objectives: - To determine the pharmacokinetics of oral Aza-TdC - To document preliminary evidence of Aza-TdC activity - To determine effect of study treatment on re-expression of select genes silenced by methylation in circulating tumor cells Eligibility: -Patients greater than or equal to 18 years of age must have histologically documented solid tumors whose disease has progressed on standard therapy or for which there is no available standard therapy Study Design: - Aza-TdC will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles. - The trial will follow an accelerated titration design, changing to a traditional 3+3 dose escalation design (3-6 patients per cohort) once specified toxicity criteria are met. Intrapatient dose escalation will be allowed. - Blood samples will be obtained for pharmacokinetic analysis and to isolate circulating tumor cells to assess re-expression of genes silenced by methylation. More... »

URL

https://clinicaltrials.gov/show/NCT03366116

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the instruction book for each cell. In some people with cancer, the genes that might have slowed the growth of their tumor were turned off. Researchers want to see if a new drug can turn the genes back on and slow the tumor growth. The drug is called Aza-TdC. Objective: To test the safety of Aza-TdC, and to find out the dose of this drug that can be safely given to humans. Eligibility: People ages 18 and older who have advanced cancer that has gotten worse after standard treatment, or for which no effective therapy exists Design: Participants will be screened with: Medical history Blood and urine tests Scans to measure their tumors Test to measure the electrical activity of the heart Participants will take the study drug by mouth. The drug is given in cycles. Each cycle is 21 days (3 weeks) long. Week 1 and week 2: participants will take the study drug once a day for 5 days. Then they will have 2 days without the drug. Week 3: no study drug is taken. This completes one cycle of treatment. For cycle 1, participants will repeat the screening tests several times. For all other cycles, participants will have blood tests and pregnancy tests. They will have scans of their tumor every 6 weeks. The cycle will be repeated as long as the participant tolerates the drug and the cancer is either stable or gets better. Sponsoring Institute: National Cancer Institute\n\nDetailed Description\nBackground - Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two DNA hypomethylating nucleosides, 5-azacytidine (azacytidine) and 5-aza-2'-deoxycytidine (decitabine) have been approved by the FDA for the treatment of patients with myelodysplastic syndromes and certain leukemias. - The nucleoside analog 5-aza-4 -thio-2 -deoxycytidine (Aza-TdC) is incorporated into DNA, where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. DNMT1 can become trapped in a covalent complex with DNA, thus depleting free enzyme and inhibiting the normal maintenance methylation of CpG sites, resulting in re-activation of tumor suppressor genes. - Data suggest a correlation between Aza-TdC activity in solid tumor xenograft models and decreased levels of DNMT1. - Aza-TdC offers an improvement over traditional DNA methyltransferase inhibitors by virtue of a higher incorporation rate into DNA at lower levels of cytotoxicity; Aza-TdC has greater antitumor activity than another recently developed DNMT1 inhibitor, TdCyd, in some solid tumor xenograft models. Treatment with Aza-TdC is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules. Primary Objective: -To establish the safety, tolerability, and MTD of oral Aza-TdC administered daily for 5 days a week for 2 weeks, with one week off, q 21-day cycles, to patients with refractory solid tumors Secondary Objectives: - To determine the pharmacokinetics of oral Aza-TdC - To document preliminary evidence of Aza-TdC activity - To determine effect of study treatment on re-expression of select genes silenced by methylation in circulating tumor cells Eligibility: -Patients greater than or equal to 18 years of age must have histologically documented solid tumors whose disease has progressed on standard therapy or for which there is no available standard therapy Study Design: - Aza-TdC will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles. - The trial will follow an accelerated titration design, changing to a traditional 3+3 dose escalation design (3-6 patients per cohort) once specified toxicity criteria are met. Intrapatient dose escalation will be allowed. - Blood samples will be obtained for pharmacokinetic analysis and to isolate circulating tumor cells to assess re-expression of genes silenced by methylation.", 
    "endDate": "2021-09-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03366116", 
    "keywords": [
      "Phase I trial", 
      "AZA", 
      "advanced solid tumor", 
      "blood", 
      "tissue", 
      "tumor cell", 
      "gene", 
      "DNA", 
      "Book", 
      "cell", 
      "Neoplasm", 
      "drug", 
      "tumor growth", 
      "safety", 
      "dose", 
      "human", 
      "eligibility", 
      "age", 
      "advanced cancer", 
      "standard treatment", 
      "effective therapy", 
      "medical history", 
      "urine test", 
      "electrical activity", 
      "heart", 
      "study drug", 
      "mouth", 
      "cycle", 
      "repeat", 
      "screening test", 
      "Hematologic Test", 
      "pregnancy", 
      "Institute", 
      "National Cancer Institute", 
      "detailed description", 
      "methylation", 
      "epigenetic mechanism", 
      "Carcinogenesis", 
      "agent", 
      "clinical interest", 
      "tumor suppressor gene", 
      "nucleoside", 
      "Azacitidine", 
      "decitabine", 
      "FDA", 
      "patient", 
      "myelodysplastic syndrome", 
      "certain leukemia", 
      "nucleoside analog", 
      "Catalytic Domain", 
      "DNA methyltransferases", 
      "DNMT1", 
      "methyltransferase", 
      "hypermethylation", 
      "silencing", 
      "covalent complex", 
      "free enzyme", 
      "normal maintenance", 
      "CpG site", 
      "re-activation", 
      "correlation", 
      "tumor xenograft model", 
      "decreased level", 
      "improvement", 
      "virtue", 
      "incorporation", 
      "low level", 
      "cytotoxicity", 
      "antitumor activity", 
      "inhibitor", 
      "inhibition", 
      "depletion", 
      "oral dose", 
      "dosing schedule", 
      "tolerability", 
      "MTD", 
      "secondary objective", 
      "pharmacokinetics", 
      "preliminary evidence", 
      "study treatment", 
      "re-expression", 
      "select gene", 
      "solid tumor", 
      "disease", 
      "standard therapy", 
      "study design", 
      "trial", 
      "titration", 
      "dose escalation", 
      "cohort", 
      "criterion", 
      "blood sample", 
      "pharmacokinetic analysis"
    ], 
    "name": "Phase I Trial of 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in Patients With Advanced Solid Tumors", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03366116"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00026.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.48336.3a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.410305.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2018-11-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.2217/epi.09.44", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008425010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1081/ncn-120026872", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009270510"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-014-2503-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041848796", 
          "https://doi.org/10.1007/s00280-014-2503-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03366116"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03366116'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03366116'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03366116'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03366116'


 

This table displays all metadata directly associated to this object as RDF triples.

124 TRIPLES      16 PREDICATES      112 URIs      102 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03366116 schema:about anzsrc-for:3142
2 schema:description Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the instruction book for each cell. In some people with cancer, the genes that might have slowed the growth of their tumor were turned off. Researchers want to see if a new drug can turn the genes back on and slow the tumor growth. The drug is called Aza-TdC. Objective: To test the safety of Aza-TdC, and to find out the dose of this drug that can be safely given to humans. Eligibility: People ages 18 and older who have advanced cancer that has gotten worse after standard treatment, or for which no effective therapy exists Design: Participants will be screened with: Medical history Blood and urine tests Scans to measure their tumors Test to measure the electrical activity of the heart Participants will take the study drug by mouth. The drug is given in cycles. Each cycle is 21 days (3 weeks) long. Week 1 and week 2: participants will take the study drug once a day for 5 days. Then they will have 2 days without the drug. Week 3: no study drug is taken. This completes one cycle of treatment. For cycle 1, participants will repeat the screening tests several times. For all other cycles, participants will have blood tests and pregnancy tests. They will have scans of their tumor every 6 weeks. The cycle will be repeated as long as the participant tolerates the drug and the cancer is either stable or gets better. Sponsoring Institute: National Cancer Institute Detailed Description Background - Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two DNA hypomethylating nucleosides, 5-azacytidine (azacytidine) and 5-aza-2'-deoxycytidine (decitabine) have been approved by the FDA for the treatment of patients with myelodysplastic syndromes and certain leukemias. - The nucleoside analog 5-aza-4 -thio-2 -deoxycytidine (Aza-TdC) is incorporated into DNA, where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. DNMT1 can become trapped in a covalent complex with DNA, thus depleting free enzyme and inhibiting the normal maintenance methylation of CpG sites, resulting in re-activation of tumor suppressor genes. - Data suggest a correlation between Aza-TdC activity in solid tumor xenograft models and decreased levels of DNMT1. - Aza-TdC offers an improvement over traditional DNA methyltransferase inhibitors by virtue of a higher incorporation rate into DNA at lower levels of cytotoxicity; Aza-TdC has greater antitumor activity than another recently developed DNMT1 inhibitor, TdCyd, in some solid tumor xenograft models. Treatment with Aza-TdC is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules. Primary Objective: -To establish the safety, tolerability, and MTD of oral Aza-TdC administered daily for 5 days a week for 2 weeks, with one week off, q 21-day cycles, to patients with refractory solid tumors Secondary Objectives: - To determine the pharmacokinetics of oral Aza-TdC - To document preliminary evidence of Aza-TdC activity - To determine effect of study treatment on re-expression of select genes silenced by methylation in circulating tumor cells Eligibility: -Patients greater than or equal to 18 years of age must have histologically documented solid tumors whose disease has progressed on standard therapy or for which there is no available standard therapy Study Design: - Aza-TdC will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles. - The trial will follow an accelerated titration design, changing to a traditional 3+3 dose escalation design (3-6 patients per cohort) once specified toxicity criteria are met. Intrapatient dose escalation will be allowed. - Blood samples will be obtained for pharmacokinetic analysis and to isolate circulating tumor cells to assess re-expression of genes silenced by methylation.
3 schema:endDate 2021-09-01T00:00:00Z
4 schema:keywords AZA
5 Azacitidine
6 Book
7 Carcinogenesis
8 Catalytic Domain
9 CpG site
10 DNA
11 DNA methyltransferases
12 DNMT1
13 FDA
14 Hematologic Test
15 Institute
16 MTD
17 National Cancer Institute
18 Neoplasm
19 Phase I trial
20 advanced cancer
21 advanced solid tumor
22 age
23 agent
24 antitumor activity
25 blood
26 blood sample
27 cell
28 certain leukemia
29 clinical interest
30 cohort
31 correlation
32 covalent complex
33 criterion
34 cycle
35 cytotoxicity
36 decitabine
37 decreased level
38 depletion
39 detailed description
40 disease
41 dose
42 dose escalation
43 dosing schedule
44 drug
45 effective therapy
46 electrical activity
47 eligibility
48 epigenetic mechanism
49 free enzyme
50 gene
51 heart
52 human
53 hypermethylation
54 improvement
55 incorporation
56 inhibition
57 inhibitor
58 low level
59 medical history
60 methylation
61 methyltransferase
62 mouth
63 myelodysplastic syndrome
64 normal maintenance
65 nucleoside
66 nucleoside analog
67 oral dose
68 patient
69 pharmacokinetic analysis
70 pharmacokinetics
71 pregnancy
72 preliminary evidence
73 re-activation
74 re-expression
75 repeat
76 safety
77 screening test
78 secondary objective
79 select gene
80 silencing
81 solid tumor
82 standard therapy
83 standard treatment
84 study design
85 study drug
86 study treatment
87 tissue
88 titration
89 tolerability
90 trial
91 tumor cell
92 tumor growth
93 tumor suppressor gene
94 tumor xenograft model
95 urine test
96 virtue
97 schema:name Phase I Trial of 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in Patients With Advanced Solid Tumors
98 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03366116
99 schema:sdDatePublished 2019-03-07T15:27
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher N3a80f1d7ce0641c185fe2aaac600632a
102 schema:sponsor https://www.grid.ac/institutes/grid.410305.3
103 https://www.grid.ac/institutes/grid.48336.3a
104 schema:startDate 2018-11-01T00:00:00Z
105 schema:subjectOf sg:pub.10.1007/s00280-014-2503-z
106 https://doi.org/10.1081/ncn-120026872
107 https://doi.org/10.2217/epi.09.44
108 schema:url https://clinicaltrials.gov/show/NCT03366116
109 sgo:license sg:explorer/license/
110 sgo:sdDataset clinical_trials
111 rdf:type schema:MedicalStudy
112 N3a80f1d7ce0641c185fe2aaac600632a schema:name Springer Nature - SN SciGraph project
113 rdf:type schema:Organization
114 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
115 rdf:type schema:DefinedTerm
116 sg:pub.10.1007/s00280-014-2503-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1041848796
117 https://doi.org/10.1007/s00280-014-2503-z
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1081/ncn-120026872 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009270510
120 rdf:type schema:CreativeWork
121 https://doi.org/10.2217/epi.09.44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008425010
122 rdf:type schema:CreativeWork
123 https://www.grid.ac/institutes/grid.410305.3 schema:Organization
124 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...